Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer

Table 1 Baseline characteristics in group immune checkpoint inhibitor and group non-immune checkpoint inhibitor, n (%)

Variable	Group ICI (n = 53)	Group non-ICI (n = 29)	P value
Age (years)
≥ 65	31 (58.5)	12 (41.4)	0.138
< 65	22 (41.5)	17 (58.6)	-
Gender
Male	39 (73.6)	21 (72.4)	0.909
Female	14 (26.4)	8 (27.6)	-
ECOG
0-1	47 (88.7)	27 (93.1)	0.798
2	6 (13.3)	2 (6.9)	-
C-TNM
III	39 (73.6)	23 (79.3)	0.564
IVa	14 (26.4)	6 (20.7)	-
Tumor location
Upper	30 (56.6)	22 (75.9)	0.174
Middle	13 (24.5)	3 (10.3)	-
Lower	10 (18.9)	4 (13.8)	-
Differentiation degree
Poorly	22 (41.5)	16 (55.2)	0.236
Moderately-highly	31 (58.5)	13 (44.8)	-
Vascular tumor embolus	29 (54.7)	21 (72.4)	0.116
Nerve infiltration	29 (54.7)	22 (75.9)	0.059
Tumor size
> 5 cm	11 (20.8)	11 (37.9)	0.093
≤ 5 cm	42 (79.2)	18 (62.1)	-

ICI: Immune checkpoint inhibitor; ECOG: Eastern Cooperative Oncology Group; C-TNM: Tumor-node-metastasis.